Nature News

Tumor line shapes BRCA-mediated phenotypes

1.

Wooster, R. et al. Identification of BRCA2 breast most cancers susceptibility gene. Nature 378, 789-792 (1995).

2

Miki, Y. et al. A powerful candidate for the breast most cancers and ovarian BRCA1 susceptibility gene. Science 266, 66-71 (1994).

three

Roy, R., Chun, J. and Powell, S. BRCA1 and BRCA2: totally different roles in a standard pathway for genome safety. Nat. Rev. Most cancers 12, 68-78 (2011).

four

Kuchenbaecker, Okay.B. et al. Dangers of breast, ovarian and contralateral breast most cancers in BRCA1 and BRCA2 mutation carriers. Jam. Med. Assoc. 317, 2402 to 2416 (2017).

5

Paluch-Shimon, S. et al. Prevention and screening in carriers of the BRCA mutation and different hereditary breast / ovarian most cancers syndromes: ESMO scientific observe tips for most cancers prevention and screening. Ann. Oncol. 27 (Suppl.5), v103 to v110 (2016).

6

Maxwell, Okay.N. et al. BRCA locus-specific heterozygosity loss in BRCA1 and BRCA2 germline carriers. Nat. Frequent. eight, 319 (2017).

7.

Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Most cancers 16, 110-120 (2016).

eight

Yu, V.P. et al. International chromosomal rearrangements and genetic exchanges between non-homologous chromosomes after inactivation of BRCA2. Genes Dev. 14, 1400-1406 (2000).

9

Moynahan, M.E., Pierce, A.J. and Jasin, M. BRCA2 is required for the directed restore of chromosome ruptures homology. Mol. Cell 7, 263-272 (2001).

ten.

Moynahan, M.E., J.W., Koller, B.H. and Jasin, M.Brca1 management homology-directed DNA restore. Mol. Cell four, 511-518 (1999).

11

Alexandrov, L.B. et al. Signatures of mutational processes in human most cancers. Nature 500, 415-421 (2013).

12

Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency primarily based on mutational signatures. Nat. Med. 23, 517-525 (2017).

13

Marquard, A. M. et al. The pan-cancer evaluation of genomic scar signatures related to homologous recombination deficiency suggests new indications for present anticancer medicine. Biomark. Res. three, 9 (2015).

14

Moore, Okay. et al. Upkeep olaparib in sufferers with newly identified superior ovarian most cancers. N. Engl. J. Med. 379, 2495-2505 (2018).

15

Robson, M. et al. Olaparib for metastatic breast most cancers in sufferers with a BRCA germline mutation. N. Engl. J. Med. 377, 523-533 (2017).

16

Manickam, Okay. et al. Screening primarily based on the exome sequencing of pathogenic variants anticipated from BRCA1 / 2 in grownup contributors of the biobank. JAMA Community Open 1, e182140 (2018).

17

Mandelker, D. et al. Detection of the mutation in sufferers with superior most cancers by common sequencing of cancer-related genes in tumor and regular DNA checks in opposition to tips. Jam. Med. Assoc. 318, 825-835 (2017).

18

Cheng, D. T. et al. Full detection of germline variants by MSK-IMPACT, a scientific diagnostic platform for molecular oncology of strong tumors and concomitant most cancers susceptibility checks. BMC Med. Genomics 10, 33 (2017).

19

Zehir, A. et al. The mutational panorama of metastatic most cancers revealed by the possible scientific sequencing of 10,000 sufferers. Nat. Med. 23, 703-713 (2017).

20

Levy-Lahad, E. & Friedman, E. Most cancers Dangers in BRCA1 and BRCA2 Mutations. French. J. Most cancers 96, 11-15 (2007).

21

Mersch, J. et al. Cancers related to BRCA1 and BRCA2 mutations apart from breast and ovarian cancers. Most cancers 121, 269-275 (2015).

22

Scully, R. & Livingston, D. M. Looking for tumor suppressor features of BRCA1 and BRCA2. Nature 408, 429-432 (2000).

23

Timms, Okay.M. et al. Affiliation of BRCA1 / 2 defects with genomic scores predictive of a DNA harm restore deficit amongst breast most cancers subtypes. Breast most cancers Res. 16, 475 (2014).

24

Mouw, Okay.W., Goldberg, M.S., Konstantinopoulos, P.A. & D'Andrea, A.D. Harm to DNA and restore of biomarkers of the immunotherapeutic response. Most cancers Discov. 7, 675-693 (2017).

25

Nolan, E. et al. Mixed blocking of the immune management level as a therapeutic technique for BRCA1-mutated breast most cancers. Sci. Trad. Med. 9, eaal4922 (2017).

26

Drilon, A. et al. Efficacy of larotrectinib in TRK fusion cancers in adults and youngsters. N. Engl. J. Med. 378, 731-739 (2018).

27

Le, D. T. et al. A mismatch restore deficiency predicts the response of strong tumors to PD-1 blockade. Science 357, 409-413 (2017).

28

Cheng, D. T. et al. Memorial Sloan Kettering – Built-in Mutation of Focused Most cancers Targets (MSK-IMPACT): Scientific Subsequent Era Sequencing Trial Primarily based on Hybridization Seize for Molecular Oncology of Strong Tumors. J. Mol. Diagn. 17, 251-264 (2015).

29

Coombs, C.C. et al. Clonal hematopoiesis-related remedy in sufferers with non-hematologic most cancers is frequent and related to hostile scientific outcomes. Cell Stem Cell 21, 374-382 (2017).

30

Karczewski, Okay.J. et al. The variation on 141,456 exomes and human genomes reveals the spectrum of intolerance to lack of operate between genes encoding human proteins. Pre-print on https://www.bioRxiv.org/content material/10.1101/531210v2 (2019).

31.

Spurdle, A.B. et al. ENIGMA – Proof-based Community for the Interpretation of Germ-Line Mutant Alleles: An Worldwide Initiative to Assess the Danger and Scientific Significance Related to BRCA1 and BRCA2 Gene Sequence Variation. Hum. Mutat. 33, 2-7 (2012).

32

Findlay, G.M. et al. Correct classification of BRCA1 variants with saturation genome modifying. Nature 562, 217-222 (2018).

33

Chakravarty, D. et al. OncoKB: a data base in precision oncology. JCO Summary. Oncol. https://doi.org/10.1200/PO.17.00011 (2017).

34

Niu, B. et al. MSIsensor: Detection of microsatellite instability utilizing regular coupled tumor sequence knowledge. Bioinformatics 30, 1015-1016 (2014).

35

Middha, S. et al. Dependable analysis of the instability of pan-cancer microsatellites with the assistance of next-generation focused sequencing knowledge. JCO Summary. Oncol. https://doi.org/10.1200/PO.17.00084 (2017).

36

Johnson, B.E. et al. Mutual evaluation reveals the origin and evolution of recurrent gliomas induced by remedy. Science 343, 189-193 (2014).

37

Shen, R. & Seshan, V. E. FACETS: Clone-specific copy and clonal heterogeneity evaluation device for alleles for prime throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).

38

Bielski, C.M. et al. The doubling of the genome shapes the evolution and prognosis of superior cancers. Nat. Broom. 50, 1189-1195 (2018).

39

McGranahan, N. et al. Clonal standing of actionable driving occasions and timing of mutational processes in the middle of most cancers. Sci. Trad. Med. 7, 283ra54 (2015).

40

Mose, L.E., Wilkerson, M.D., Hayes, D.N., Peru, C.M. and Parker, J.S.A.RA: Improved detection of indel coding through assembly-based realignment. Bioinformatics 30, 2813-2815 (2014).

41

DePristo, M.A. et al. A framework for variation discovery and genotyping utilizing next-generation DNA sequencing knowledge. Nat. Broom. 43, 491-498 (2011).

42

Cibulskis, Okay. et al. Delicate detection of somatic level mutations in impure and heterogeneous most cancers samples. Nat. Biotechnol. 31, 213-219 (2013).

43

Lai, Z. et al. VarDict: an revolutionary and versatile variant for next-generation sequencing in most cancers analysis. Nucleic Acids Res. 44, e108 (2016).

44

Chang, M.T. et al. Accelerated discovery of purposeful mutant alleles in most cancers. Most cancers Discov. eight, 174-183 (2018).

45

Chang, M.T. et al. Figuring out recurrent mutations in most cancers reveals intensive lineage variety and mutation specificity. Nat. Biotechnol. 34, 155-163 (2016).

46

Alexandrov, L.B. et al. Mutation-type clock processes in human somatic cells. Nat. Broom. 47, 1402-1407 (2015).

47

Wang, Y. Okay. et al. The genomic penalties of aberrant DNA restore mechanisms stratify histotypes of ovarian most cancers. Nat. Broom. 49, 856-865 (2017).

48.

Huang, Okay.-L. et al. Germinal pathogenic variants in 10,389 grownup cancers. Cell 173, 355-370 (2018).

49

Knijnenburg, T.A. et al. Genomic and molecular panorama of DNA restore harm deficit within the atlas of the most cancers genome. Cell Rep. 23, 239-254 (2018).

Leave a Reply

Your email address will not be published. Required fields are marked *